Search results
Results from the WOW.Com Content Network
However, because of its rare but serious side effects of neutropenia and thrombotic microangiopathy it was primarily used in patients in whom aspirin was not tolerated, or in whom dual antiplatelet therapy was desirable. With the advent of newer and safer antiplatelet drugs such as clopidogrel and ticagrelor, its use remained limited.
Common side effects include headache, nausea, easy bruising, itching, and heartburn. [10] More severe side effects include bleeding and thrombotic thrombocytopenic purpura. [10] While there is no evidence of harm from use during pregnancy, such use has not been well studied. [3] Clopidogrel is in the thienopyridine-class of antiplatelets. [10]
Tirofiban, sold under the brand name Aggrastat, is an antiplatelet medication.It belongs to a class of antiplatelets named glycoprotein IIb/IIIa inhibitors.Tirofiban is a small molecule inhibitor of the protein-protein interaction between fibrinogen and the platelet integrin receptor GP IIb/IIIa and is the first drug candidate whose origins can be traced to a pharmacophore-based virtual ...
Antiplatelet therapy with one or more of these drugs decreases the ability of blood clots to form by interfering with the platelet activation process in primary hemostasis. Antiplatelet drugs can reversibly or irreversibly inhibit the process involved in platelet activation resulting in decreased tendency of platelets to adhere to one another ...
Some dietary supplements can cause side effects and harm to the mother or unborn child. [5] Pregnant women should discuss all dietary supplements with their health care professional to determine the appropriate dosage and which supplements are safe during pregnancy. [5]
Common side effects include bleeding. [8] Other serious side effects may include spinal hematoma and anaphylaxis. [8] It is unclear if use in pregnancy and breastfeeding is safe. [1] Compared to warfarin it has fewer interactions with other medications. [9] It works by blocking the activity of the clotting protein factor Xa. [8]
The drug is produced by AstraZeneca. 90 mg tablet of Brilinta. The most common side effects include dyspnea (difficulty breathing), bleeding and raised uric acid level in the blood. [6] It was approved for medical use in the European Union in December 2010, [6] [8] [9] and in the United States in July 2011.
Eptifibatide is used to reduce the risk of acute cardiac ischemic events (death and/or myocardial infarction) in patients with unstable angina or non-ST-segment-elevation (e.g., non-Q-wave) myocardial infarction (i.e., non-ST-segment elevation acute coronary syndromes) both in patients who are to receive non surgery (conservative) medical treatment and those undergoing percutaneous coronary ...